Gleave M - Search Results

1

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. Aggarwal R, et al. Among authors: gleave m. J Clin Oncol. 2018 Aug 20;36(24):2492-2503. doi: 10.1200/JCO.2017.77.6880. Epub 2018 Jul 9. J Clin Oncol. 2018. PMID: 29985747 Free PMC article. Clinical Trial.

2

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.

Miyake H, Chi KN, Gleave ME. Miyake H, et al. Among authors: gleave me. Clin Cancer Res. 2000 May;6(5):1655-63. Clin Cancer Res. 2000. PMID: 10815883

3

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.

Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Gleave ME, et al. Urology. 2001 Aug;58(2 Suppl 1):39-49. doi: 10.1016/s0090-4295(01)01241-9. Urology. 2001. PMID: 11502446

4

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S, Tolcher AW. Chi KN, et al. Among authors: gleave me. Clin Cancer Res. 2001 Dec;7(12):3920-7. Clin Cancer Res. 2001. PMID: 11751483 Clinical Trial.

5

Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, Leung S. Gleave ME, et al. Invest New Drugs. 2002 May;20(2):145-58. doi: 10.1023/a:1015694802521. Invest New Drugs. 2002. PMID: 12099575 Review.

6

Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.

Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME. Zellweger T, et al. Clin Cancer Res. 2002 Oct;8(10):3276-84. Clin Cancer Res. 2002. PMID: 12374699

7

What's hot in the prostate?

Gleave M, Evans C. Gleave M, et al. Prostate Cancer Prostatic Dis. 2002;5(3):168-71. doi: 10.1038/sj.pcan.4500618. Prostate Cancer Prostatic Dis. 2002. PMID: 12496976 No abstract available.

8

Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.

Gleave M, Nelson C, Chi K. Gleave M, et al. Curr Drug Targets. 2003 Apr;4(3):209-21. doi: 10.2174/1389450033491190. Curr Drug Targets. 2003. PMID: 12643471 Review.

9

What's hot in the prostate?

Gleave M, Evans CP. Gleave M, et al. Prostate Cancer Prostatic Dis. 2003;6(3):200-3. doi: 10.1038/sj.pcan.4500678. Prostate Cancer Prostatic Dis. 2003. PMID: 12970721 No abstract available.

10

What's hot in the prostate?

Gleave M, Evans CP. Gleave M, et al. Prostate Cancer Prostatic Dis. 2003;6(4):268-71. doi: 10.1038/sj.pcan.4500699. Prostate Cancer Prostatic Dis. 2003. PMID: 14663465 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

689 results

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

689 results